What You Need to Know About Triple-Negative Breast Cancer
Among all the types of breast cancers, triple-negative breast cancer is the rarest. This type of cancer has a mortality rate of only 1%. It is very dangerous for people with the disease and treatment options can be confusing. Read on to find out more about this illness and what you can do to help treat it.
Symptoms
Symptoms of triple-negative breast cancer can range from a lump in the breast to thickened skin and dry skin. It’s important to know the symptoms of this type of cancer before seeking treatment. Typically, it’s diagnosed when a woman has an abnormal mammogram or ultrasound. If a person’s symptoms are persistent, they may need a biopsy to determine the exact type of breast cancer they have.
The risk of recurrence for this type of breast cancer is higher than for other types. It is also more likely to spread to other parts of the body. There are several different types of treatment for this type of cancer. The treatment options depend on the size of the tumor and the stage of cancer.
The most common type of treatment for triple-negative breast cancer is surgery. The surgery may be used to remove a part of the breast or the entire breast. Sometimes, the surgery may be combined with chemotherapy. This helps shrink the tumor before the surgery and decreases the chance of recurrence.
Surgical treatment for this type of cancer includes mastectomy, lumpectomy, and radiation therapy. The treatment may cause side effects, such as fatigue, pain, and mental fuzziness. Each person’s reaction to these side effects will vary. It’s a good idea to talk with your doctor to find out if you should take any medication for these side effects.
The treatment for this type of cancer is also determined by the stage and the genetic makeup of the tumor. Early-stage TNBC usually receives chemotherapy. If the tumor has spread to the lymph nodes or bones, it may require radiation therapy. It is also possible to treat metastatic TNBC using targeted therapies.
The treatment for triple-negative breast cancer is different from other forms of cancer. This type is generally more aggressive and tends to be more difficult to treat. A mastectomy or lumpectomy is often required if the patient has a large tumor.
The diagnosis of triple-negative breast cancer can be very frightening. It’s important to get the right treatment to prevent a recurrence. Some treatment options for this type of cancer include chemotherapy, immunotherapy, and radiation.
Diagnosis
Approximately 13 in every 100,000 women develop triple-negative breast cancer annually. The reason for the increased risk of developing this disease is unclear. Researchers are trying to determine the cause and are looking into new treatments.
The symptoms of triple-negative breast cancer include thickened skin, dry skin, nipple retraction, swelling, and pain. Women with this type of cancer are also more likely to develop metastasis.
If you have a family history of breast cancer, you may be more at risk. If you have a gene mutation known as BRCA1, it makes your cells more susceptible to cancer. Your doctor may test for the presence of the mutation or take you to a specialist breast clinic to evaluate your risk.
In addition, you may have genetic counseling. The MacDonald Cancer Risk Evaluation Center at Penn Medicine Lancaster General Health is a great resource for finding out your risk and receiving genetic counseling. You can also contact your GP to see if they recommend you go to a specialist breast clinic.
Your healthcare provider will determine if you need to undergo a biopsy. This procedure involves removing tissue from your breast and checking it for signs of cancer. The pathologist will look at the cells under a microscope to determine if they are precancerous or not. He or she will also check to see if the cells have any of the hormone receptors estrogen, progesterone, and HER2 in them.
Your doctor will then decide if you need to undergo surgery to remove the cancerous tumor. For small tumors, you might be able to have a lumpectomy, but for larger tumors, you might need to have a mastectomy.
You might also have chemotherapy after surgery. Chemotherapy works by killing cancer cells and reducing your risk of having them recur. This is especially important for patients who have large tumors.
The best way to treat triple-negative breast cancer is by undergoing a combination of chemotherapy, radiation, and surgery. The treatment plan will depend on the size and stage of the cancer, your gender, the extent of the tumor, and your symptoms.
Treatment options
Whether you are a breast cancer patient or a family member of a triple-negative breast cancer patient, it is important that you understand the treatment options available. Treatment for this type of cancer may involve a combination of surgery, chemotherapy, and radiation. The specific treatments used will depend on the stage of the disease and the size of the tumor.
One of the most common types of treatment for triple-negative breast cancer is chemotherapy. This is used to shrink the tumor and prevent it from growing or reoccurring. Usually, chemotherapy is given as a systemic treatment that moves through the bloodstream. Depending on the stage of cancer and the size of the tumor, chemotherapy may be given before or after surgery.
Another exciting treatment option is immunotherapy. This type of therapy involves the use of drugs that target the HER2 and PD-L1 proteins. These proteins help the body’s immune system fight off cancer cells.
Other treatment options include 5-aza-2′-deoxycytidine, which is FDA-approved for certain blood cancers. It is also an effective treatment for triple-negative breast cancer. This chemotherapy drug is taken for 18 to 24 weeks.
For patients with large tumors, radiation therapy is an effective treatment. This therapy targets the breast and the lymph nodes. For smaller tumors, lumpectomy or mastectomy is recommended.
A new drug, pembrolizumab, is a promising treatment for advanced triple-negative breast cancer. This drug is an antibody-drug conjugate that targets the PD-L1 protein. This protein is present in 20 percent of triple-negative cancers.
Checkpoint inhibitors, which include monoclonal antibody drugs, are used to slow the growth of tumors. These medicines may be used in combination with chemotherapy for advanced triple-negative breast cancer.
The best treatments for triple-negative breast cancer are tailored to the unique needs of each individual. Treatment options are also dependent on the stage of cancer and the size and location of the tumor. The odds of surviving are based on early detection.
If you or a loved one is a triple-negative breast cancer patient, you may be eligible to participate in a clinical trial. These trials are a great way for you to explore promising therapies before they are widely available.
Survival rates
Typically, triple-negative breast cancer is treated with a combination of surgery, chemotherapy, and radiation. It has lower survival rates in the early years and is more likely to recur than other types of breast cancer. However, there are new treatments that can increase survival rates.
The 5-year survival rate for triple-negative breast cancer is about 77%. This is higher than the 5-year survival rate for non-TNBC, which is about 75%. It also has a better overall survival rate than hormone receptor-positive breast cancer.
The 5-year survival rate for localized triple-negative breast cancer is 91 percent. It is more likely to spread to the nearby lymph nodes and other areas.
The five-year survival rate for distant triple-negative breast cancer is 12%. It is not known how effective immunotherapy will be, but it is considered to be a potential treatment option.
It is important to note that the 5-year survival rate is the average for the patients involved. It is based on statistics that are compiled from large numbers of people. Each person has different cancer and will have a different outlook. It is also important to remember that these statistics are not meant to predict a specific outcome.
The risk of recurrence is high in the first three years of treatment. During this period, about 40 percent of patients will have a recurrence. After treatment, the risk of recurrence will fall quickly.
The 5-year relative survival rate is based on the stage of cancer. It is about 65% for regional and 12% for distant triple-negative breast cancer. It is not known how much of this difference is due to the type of tumor.
The 5-year overall survival rate for breast cancer is about 78.6%. It is nearly 100% for stage 1. Juiz de Fora, Brazil was the location of the study. It consisted of 447 women. The age range of the participants was 29 to 88. The number of patients with carcinoma in situ was a small percentage of the total.
The age of the woman and the stage of cancer at diagnosis can affect the outlook for triple-negative breast cancer. Some people live much longer than five years after being diagnosed. It is also important to remember that the outlook is dependent on the size of the tumor when the cancer is discovered.
Health Sources:
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/
